Charles J. Sherr, MD, PhD
Charles J. Sherr, MD, PhD

Charles J. Sherr, MD, PhD

Member, St. Jude Faculty

  • Chair, Tumor Cell Biology Department
  • Herrick Foundation Chair
  • Investigator, Howard Hughes Medical Institute



MD – New York University School of Medicine
PhD – New York University Graduate School of Arts and Sciences

Honors & Awards

  • 2013 Elected Fellow, American Academy of Arts and Sciences
  • 2013 Elected Inaugural Fellow, Academy of the American Association for Cancer Research
  • 2013 American-Italian Cancer Foundation Prize
  • 2010 Elected Fellow, American Association for the Advancement of Science
  • 2004 Elected to the US Institute of Medicine
  • 2004 General Motors Cancer Foundation Mott Prize
  • 2003 AACR Landon Prize for Basic Cancer Research
  • 2000 Bristol Myers-Squibb Achievement Award for Basic Cancer Research
  • 2000 AACR Pezcoller Award
  • 1995 Elected to the US National Academy of Sciences

Research Interests

Our laboratory has traditionally focused on the mechanisms by which mitogens relay proliferative signals that affect progression through the mammalian cell division cycle. Current projects emphasize the rate limiting effects of cyclins and cyclin-dependent kinases (CDKs) on G1 phase progression; the role of CDK inhibitors (INK4 and Cip/Kip proteins) in cell cycle control, organismal development, and tumorigenesis in vivo; the activity of particular tumor suppressors, including INK4A-ARF, p53, and RB, in cell line establishment, senescence, stem cell biology, and protecting against oncogenic insults. Postdoctoral fellows and graduate students receive joint supervision by Drs. Roussel and Sherr in a multi-disciplinary program that seeks to maximize trainees’ abilities to successfully perform novel and speculative experiments.

Selected Publications

Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov 6(4):1-15, 2016. [EPub ahead of print 2015, PMID 26658964]

Sharpless NE, Sherr CJ. Forging a signature of in vivo senescence. Nat Rev Cancer 15(7):397-408, 2015.

Appelmann I, Rillahan CD, de Stanchina E, Carbonetti G, Chen C, Lowe SW, Sherr CJ. Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL. Blood 125(9):1444-1451, 2015.

Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev 28(16):1800-1814, 2014.

Li C, Qi R, Singleterry R, Hyle J, Balch A, Li X, Sublett J, Berns H, Valentine M, Valentine V, Sherr CJ. Simultaneous gene editing by injection of mRNAs encoding transcription activator-like effector nucleases into mouse zygotes. Mol Cell Biol 34(9):1649-1658, 2014.

Li C, Finkelstein D, Sherr CJ. Arf tumor suppressor and miR-205 regulate cell adhesion and formation of extraembryonic endoderm from pluripotent stem cells. Proc Natl Acad Sci USA 110(12):E1112-1121, 2013.

Sherr CJ. Ink4-Arf locus in cancer and aging. Wiley Interdiscip Rev Dev Biol (WIRES) 1(5):731-741, 2012.

Treanor LM, Volanakis EJ, Zhou S, Lu T, Sherr CJ, Sorrentino BP. Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies. Blood 117(20):5453-5462, 2011.

Boulos N, Mulder HL, Calabrese CR, Morrison JB, Rehg JE, Relling MV, Sherr CJ, Williams RT. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117(13):3585-3595, 2011.

Last update: January 2016